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OBJECTIVES We sought to investigate the association of CD14 genotype and plasma levels of soluble
(s)CD14 with risk of stable coronary artery disease (CAD), chronic infections and sensitive
markers of systemic inflammation.
BACKGROUND It has been suggested that genetic variation of the CD14 receptor with increased CD14 gene
expression might play a role in atherogenesis. A mechanistic link would consist in its
contribution to the inflammatory response seen in this disease.
METHODS We measured levels of sCD14 (g/ml; ELISA) in 312 patients with angiographically proven
CAD and stable angina pectoris, and in 477 age- and gender-matched healthy blood donors.
CD14 genotype was determined by polymerase chain reaction. In addition, seropositivity to
Chlamydia pneumoniae and Helicobacter pylori, a complete lipid profile and various sensitive
systemic markers of inflammation were measured.
RESULTS CD14 C(-260)3T genotype was not independently associated with increased risk of CAD
after multivariable adjustments (odds ratio [OR] 1.34; 95% confidence interval [CI] 0.84 to
2.16). However, sCD14 plasma levels were higher in subjects with TT genotype compared
with those with CT or CC genotype (p  0.005). Plasma levels were not different between
cases and controls (4.2  1.3 g/ml vs. 4.3  1.3 g/ml, p  NS). In multivariable logistic
regression, the OR for the presence of CAD was 1.11 (95% CI, 0.65 to 1.91) if the top
quintile of the sCD14 distribution was compared with the bottom quintile. There was no
consistent association between seropositivity to either C. pneumoniae or H. pylori, or both, and
sCD14 levels and between sCD14 levels or CD14 genotype and the various markers of
inflammation.
CONCLUSIONS These results do not confirm an independent relationship between CD14 genotypes or
plasma levels of sCD14 and risk of stable CAD in this population. (J Am Coll Cardiol
2002;40:34–42) © 2002 by the American College of Cardiology Foundation
Inflammation represents an essential feature in atheroscle-
rosis and its clinical complications (1), and it may be
triggered by infectious pathogens (2). This concept is based
on the identification of microorganisms in the atheroscle-
rotic plaque and/or seropositivity to the agent. Experimental
and seroepidemiologic studies have identified various infec-
tious agents as possible candidates (3), but mechanisms by
which these agents may induce arterial inflammation and
trigger atherogenesis remain incompletely understood.
Most of the published evidence is based on antibody
measurements, and the results from these studies remain
controversial (4–6). The presence of active infection within
the vascular wall and the hypothesis that a chronic inflam-
matory state induced by infectious agents may, nevertheless,
promote atherosclerosis have prompted the search for spe-
cific microbial products that may mediate arterial inflam-
mation. Among them, the heat shock protein (7,8) and
endotoxin (lipopolysaccharide [LPS]) (9,10) may play an
important role.
Lipopolysaccharide component of gram-negative bacteria
cell wall is considered to be responsible for several patho-
logic conditions in which these microorganisms are in-
volved. One way by which LPS could initiate the athero-
sclerotic lesion is by formation of complexes with
lipoproteins that are transported from the circulation into
the arterial wall and initiate an inflammatory response (11).
A further potential mechanism consists in the activation of
monocytes/macrophages. Lipopolysaccharide-activated
macrophages produce proinflammatory cytokines such as
tumor necrosis factor (TNF)-alpha, interleukin (IL)-1,
IL-6 (12–14) and growth factors (15). Lipopolysaccharide
induces expression of adhesion molecules in endothelial cells
(ECs) (16,17) and also stimulates smooth muscle cell
(SMC) proliferation and migration by release of platelet-
derived growth factor from monocytes (18). Moreover, it
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promotes procoagulant activity by induction of tissue factor
expression in monocytes and ECs (19,20). In addition, LPS
can induce oxidative modification of low-density lipoprotein
(LDL), a major mediator in atherogenesis (11); it increases
the levels of LDL and very low-density lipoprotein and
decreases high-density lipoprotein (HDL) levels (21). Li-
popolysaccharide is a potent stimulus for inducible nitric
oxide (NO) synthase activity, leading to the formation of
large amounts of NO, which can cause endothelial dysfunc-
tion and disruption (22).
Lipopolysaccharide is internalized by cells through the
CD14 receptor (23,24). Recent data indicate that HSP60
also activates mononuclear cells and monocyte-derivated
macrophages through CD14 signalling, sharing this path-
way with bacterial LPS (25). CD14 receptor is expressed in
considerable amounts by mature monocytes, macrophages
and activated neutrophil granulocytes. In these cells, CD14
is anchored in the cell membrane (membrane-bound CD14
[mCD14]). In addition, the soluble form (sCD14) can be
found in plasma in response to LPS stimulation, where two
major isoforms coexist (26). Lipopolysaccharide binds to the
membrane-bound CD14 on monocytes and macrophages
and activates these cells. Soluble CD14 plays an important
role in the LPS-mediated activation of cells lacking
membrane-bound CD14, so-called “CD14-negative cells”
(endothelial, epithelial and SMCs). In addition, these
CD14-negative cells are activated indirectly by cytokines
from LPS-stimulated monocytes (27). But sCD14 can also
activate monocytes independently of LPS (28). Thus, both
mCD14 and sCD14 are competing for LPS (29) and are
able to bind it (30). Changes in CD14 expression and
plasma sCD14 levels seem to be associated with an increas-
ing number of disorders like septicemia (31,32) or peri-
odontitis (33,34). In these cases, increased levels of sCD14
may be due to chronic exposure to LPS. But expression of
mCD14 is also increased in patients with noninsulin-
dependent diabetes mellitus, correlates significantly with
serum concentrations of C-reactive protein (CRP) (35), and
the density of CD14 was found to be increased in patients
with acute myocardial infarction (AMI) (36). However, to
our knowledge, no data have been published on sCD14
levels in a large group of patients with stable angina pectoris
compared with healthy subjects.
Recently, research in this field has focused on the gene of
the CD14 receptor. A polymorphism in the CD14 gene has
been reported to be associated with increased risk of AMI
(37–39). It was also suggested that the C(-260)3T change
in the promoter region affects the level of CD14 gene
expression (37). However, this polymorphism has been
found to be associated with AMI in only two small
case-control studies (37,39) and in subgroup analysis in
another retrospective study (38), but it was not associated
with future AMI, in one larger prospective study (40), and
with risk of ischemic cerebrovascular disease, in a Japanese
population (41).
Thus, because results of several studies are controversial,
we sought to determine the effect of the CD14 polymor-
phism and of plasma levels of sCD14 on coronary artery
disease (CAD) risk in a large case-control study. We further
wanted to link the CD14 genotype to sCD14 plasma levels
in patients with CAD and in healthy controls and test
whether seropositivity to Chlamydia pneumoniae, or Helico-
bacter pylori, or both, is associated with increased sCD14
levels. Finally, we were interested in the relationship be-
tween CD14 polymorphism and plasma levels of sCD14,
and sensitive systemic markers of inflammation, all reflect-
ing established predictors of coronary risk.
METHODS
Patients and controls. Patients and controls were recruited
between October 1996 and November 1997. Participation
was voluntary, and written informed consent was obtained
from each subject. The study was approved by the ethics
committee of the University of Ulm.
The case group was referred to the Department of
Cardiology at the University of Ulm Medical Center for
elective coronary angiography. A total of 312 consecutive
patients of German nationality aged 40 to 68 years with
clinically stable, angiographically confirmed CAD (50%
luminal diameter stenosis of at least one major coronary
artery), diagnosed only within the previous two years to
reduce the likelihood of survival bias, were included. Pa-
tients with acute ischemic syndromes within the previous
four weeks, on anticoagulant therapy, with acute infectious
diseases or with evidence of malignant diseases, possibly
associated with an acute phase reaction, were excluded.
The control group consisted of 476 subjects who were
occasional blood donors at the local Red Cross center
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AMI  acute myocardial infarction
BMI  body mass index
CAD  coronary artery disease
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EC  endothelial cell
HDL  high-density lipoprotein
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serving the University hospitals of Ulm. All controls had no
history of definite or suspected CAD and did not report
infections or surgery within the previous four weeks. Par-
ticipation rate was 78% in eligible patients and 84% in
eligible controls.
Frequency matching for age and gender was performed,
and a case-control ratio of 1:1.5 was intended. All subjects
underwent standardized interviews conducted by trained
interviewers. Participants were asked about medical history
including specific questions related to physician diagnosed
hypertension, diabetes and gastroduodenal disease. Further-
more, current medication, sociodemographic characteristics
and lifestyle habits were recorded.
Laboratory methods. Venous blood was drawn in the
morning under standardized conditions, and a complete
blood cell count was done (Coulter STKS chamber, Coulter
Co., Krefeld, Germany). Within 30 min, the remaining
blood was centrifuged at 3,000 g for 10 min, immediately
aliquoted and frozen at 70°C until analysis. Plasma level
of sCD14 have been determined by a commercial sandwich-
type ELISA (IBL, Hamburg, Germany), using an oligo-
clonal capture antibody, followed by an enzyme-tagged
monoclonal detection antibody. This ELISA measures only
free sCD14 and not sCD14 bound in any complex with
LPS. The two isoforms described for sCD14 are equally
well recognized. Specific anti-H. pylori IgGs were measured
by use of a commercial ELISA (H. pylori-IgG-ELISA;
Medac, Wedel, Germany). IgG antibodies against Chla-
mydia were measured by ELISA using recombinant chla-
mydial LPS (42) (Medac, Wedel, Germany), and a titer
100 was defined as seropositive.
The following markers of inflammation and hemostasis
were also determined by ELISA: IL-6 and TNF-alpha
(Quantikine, R & D Systems, Wiesbaden, Germany),
intercellular adhesion molecule (ICAM)-1 (Diaclone, Be-
sancon, France), plasminogen-activator inhibitor (PAI)-1
activity (Immuno, Heidelberg, Germany), D-dimer
(Dimertest Gold EIA, Agen Biomedical Ltd., Acacia
Ridge, Australia) and von Willebrand factor (vWF) (Hae-
mochrom, Essen, Germany). In addition, CRP determina-
tions were done by an immunoradiometric assay (range 0.05
to 10 mg/l) calibrated with the WHO reference standard
85/506 (43). Fibrinogen was measured by immunoneph-
elometry (Dade Behring, Marburg, Germany) and accord-
ing to the Clauss method. Serum amyloid A (SAA) was also
determined by immunonephelometry (Dade Behring, Mar-
burg, Germany), and, finally, measurement of plasma vis-
cosity was done in a Harkness Coulter viscometer (Coulter
Electronics, Luton, United Kingdom). Interassay coeffi-
cients of variation were 15.7% for sCD14, 7% for IL-6,
17.9% for TNF-alpha, 14.2% for ICAM-1, 12% for CRP,
7.4% for SAA, 5% for fibrinogen, 11% for PAI-1, 7.2% for
D-dimer, 15.8% for vWF and 2% for plasma viscosity. Total
and HDL cholesterol concentrations were determined by
routine enzymatic methods. Lipoprotein (Lp) (a) and apo-
proteins were determined by immunoturbidimetry on a
WAKO R-30 automated analyzer. All laboratory analyses
were done in a blinded fashion.
Analysis of the C(-260)3T polymorphism of the CD14
gene. Genomic DNA has been isolated from white blood
cells by standard method (44). Polymerase chain reaction
(PCR) was performed at total volume of 20 l (100 ng of
genomic DNA, 10 pmol of each primer, 250 mol/l of each
dNTPs and 1 U TaqDNA polymerase in the provided
reaction buffer (Boehringer Mannheim). The promoter of
CD14 receptor gene was amplified by the primers CDP-1,
5-ATCATCCTTTTCCCACACC-3 and CDP-2, 5-
AACTCTTCGGCTGCCTCT-3 under the following
conditions: an initial denaturation at 95°C for 3 min
followed by 35 cycles at 95°C for 30 s, 1 min of annealing
at 60°C, 30 s of extension at 72°C and a final extension time
of 5 min at 72°C. The PCR product was digested 3 h at
37°C with 10 U HaeIII restriction enzyme (New England
Biolabs, Beverly, Massachusetts). The DNA fragments
were separated by electrophoresis through a 2% NuSieve
agarose gel containing 0.5 g/ml of ethidium bromide and
were visualized under UV light.
Angiographic evaluation. Coronary angiography was per-
formed among cases by the Judkins method. Three different
scores were used to evaluate the angiographic severity and
extension of CAD: the number of stenosed (50% reduc-
tion of luminal diameter) or occluded vessels (one- to
three-vessel disease), the quantitative extension score (1 to
15 segments) according to the guidelines of the American
Heart Association and the qualitative and quantitative
evaluation by the Gensini score (45). Scoring of all coronary
angiograms was done visually by a single experienced
observer who was blinded to clinical and laboratory data.
The intraclass correlation coefficient for intrarater reliability
was 1.0 (one- to three-vessel disease score), 0.79 (tertiles of
the extension score) and 0.85 (tertiles of the Gensini score).
Statistical methods. Demographic and clinical character-
istics were compared in a descriptive way. Differences in the
allele and genotype distribution among cases and controls
were compared with values predicted by the Hardy-
Weinberg equilibrium. Furthermore, we used a linear re-
gression model to calculate the age- and gender-adjusted
mean values for sCD14 in patients and controls, and
according to CD14 genotypes. The same method was used
to assess the relationship of age- and gender-adjusted
plasma levels of sCD14 according to serostatus of C.
pneumoniae and serostatus of H. pylori, and the combination
of both, in patients and controls.
The association of CD14 genotype distribution with
presence of CAD was assessed by a chi-square test. Soluble
CD14 levels were measured and divided in quintiles accord-
ing to the distribution in controls. Furthermore, we used
unconditional logistic regression to assess the independent
association of sCD14 distribution (quintiles) and CD14
genotypes with CAD, while simultaneously controlling for
body mass index (BMI), duration of school education,
cigarette smoking (pack-years), alcohol consumption, his-
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tory of hypertension and history of diabetes mellitus and
HDL cholesterol values.
Blood, plasma and serum parameters are reported as
means (arithmetic or, if skewed in normality plot, geomet-
ric). To assess the association of sCD14 (upper quintile) and
CD14 genotype with markers of inflammation and hemo-
stasis and lipid parameters, we calculated age- and gender-
adjusted mean values for these markers for patients and
controls separately and the respective p value for a differ-
ence.
RESULTS
Overall, 312 patients and 476 age- and gender-matched
controls were enrolled in the study (Table 1). Patients on
average had a lower school education, had smoked more
cigarettes, had a higher BMI and, more often, had a history
of high blood pressure, diabetes mellitus and hyperlipidemia
than controls. Family status and daily alcohol consumption
habits were similar in both groups.
Approximately two-thirds of the patients (62.4%, n 
194) had a history of myocardial infarction within the
previous two years. By coronary angiography, 48% had
single-vessel disease, 34% had double-vessel disease, and
18% had triple-vessel disease.
Table 2 shows mean values and distribution of sCD14
and the allele and genotype frequencies of the CD14 gene
among cases and controls. Cases had, in general, similar
mean plasma values of sCD14 (4.21 1.3 g/ml vs. 4.28
1.3 g/ml, p  0.51, after adjustment for age and gender).
Allele and genotype frequencies in cases and controls did
not show a significant departure from the Hardy-Weinberg
equilibrium (p  0.81 and p  0.94, respectively). Further-
more, there was no difference among cases and controls with
respect to CD14 genotypes (p  0.74, adjusted for age and
gender).
However, age- and gender-adjusted mean sCD14 plasma
levels were statistically significantly higher in subjects bear-
ing the TT genotype (p  0.005) compared with heterocy-
gotes and those homocygous for the CC genotype (Table 3).
Table 4 shows that there was no association between
Table 1. Characteristics of Patients With CAD and Controls
Patients With CAD
(n  312)
Controls
(n  476)
Age (, SD) 57.7 (7.4) 55.8 (7.2)
Family status
Married (%) 85.9 83.8
School education 10 yrs (%) 69.2 59.5
Daily alcohol consumption (%) 29.5 28.8
Smoking status
Current 9.6 14.3
Ex-smoker 66.3 42.0
Never smoker (%) 24.0 43.7
Smoked pack-years () 20.3 10.9
Body mass index (kg/m2), (, SD) 27.3 (3.6) 26.3 (3.2)
History of high blood pressure (%) 57.7 20.4
History of diabetes mellitus (%) 13.5 2.7
History of hyperlipidemia (%) 67.3 20.9
HDL cholesterol (, SD) 42.4 (10.3) 51.6 (13.2)
CAD  coronary artery disease; HDL  high-density lipoprotein.
Table 2. Plasma Levels of sCD14 (g/ml), Genotype and Allele
Distribution for CD14 Polymorphism in Patients
and Controls
CAD Patients Controls p Value
sCD 14 (g/ml)
Mean* 4.21 4.28 0.51
Median (Q1–Q3) 4.07 (3.36–4.81) 4.06 (3.38–4.84)
CD 14
Genotypes n % n %
CC 75 (24.0) 126 (26.5)
CT 164 (52.6) 243 (51.1)
TT 73 (23.4) 107 (22.5) 0.74
All 312 (100) 476 (100)
Allele n % n %
C 157 (50.3) 248 (52.0)
T 155 (49.7) 228 (48.0) 0.62
*After adjustment for age and gender.
Table 3. Soluble CD14 Plasma Levels (g/ml) and CD14 C(-260)3T Polymorphism
CD14 Genotypes
p ValueCC CT TT
Patients (n  312)
sCD 14 (g/ml)
Mean* 4.08 4.02 4.48 0.03
Median (Q1–Q3) 3.81 (3.30–4.64) 4.02 (3.35–4.58) 4.30 (3.73–5.21)
Controls (n  476)
sCD 14 (g/ml)
Mean* 4.21 4.30 4.55 0.11
Median (Q1–Q3) 3.96 (3.35–4.67) 4.03 (3.34–4.83) 4.16 (3.56–5.07)
Total
sCD 14 (g/ml)
Mean* 4.19 4.21 4.56 0.005
Median (Q1–Q3) 3.87 (3.32–4.64) 4.03 (3.34–4.75) 4.20 (3.62–5.10)
*After adjustment for age and gender.
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seropositivity to either C. pneumoniae or H. pylori or both,
and plasma levels of sCD14. Also, the combination of
seropositivity to C. pneumoniae and TT genotype was not
associated with higher sCD14 plasma levels than with TT
genotype alone (data not shown).
Table 5 shows the partially and fully adjusted odds ratios
(OR) for CAD in association with sCD14 distribution and
CD14 C(-260)3T polymorphism. The OR for CAD
associated with being in the top quintile of the sCD14
distribution compared with the bottom quintile was 1.06
(95% confidence interval [CI], 0.66 to 1.70) after adjust-
ment for age and gender and 1.11 (95% CI, 0.65 to 1.91)
after adjustment for other covariates. It increased only
slightly after additional adjustment for HDL (OR, 1.14;
95% CI, 0.65 to 2.01).
Because regular aspirin intake was associated with de-
creased sCD14 plasma levels in patients with CAD (aspirin
intake 4.02 g/ml, no aspirin intake 4.16 g/ml, p  0.02
after adjustment for age and gender), aspirin medication was
additionally controlled for in multivariable analyses. This,
however, did not change the results appreciably. In contrast,
no effect of statin intake on sCD14 levels was noted.
The OR for CAD associated with bearing the TT
genotype was 1.17 (95% CI, 0.77 to 1.78) after adjustment
for age and gender and increased to 1.34 (95% CI, 0.84 to
2.16) after adjustment for other covariates. Again, addi-
tional adjustment for HDL did not change the estimate
appreciably (OR, 1.35; 95% CI, 0.82 to 2.23).
In 305 of 312 patients with angiographically determined
CAD, the severity of CAD was evaluated by three different
scores. No association between either sCD14 plasma levels
(top quintile vs. combined lower four quintiles) or CD14
genotypes and any of the three scores applied was found
(data not shown).
Plasma concentrations of CRP, fibrinogen, D-dimer,
plasma viscosity, leukocyte count, PAI-1, Lp(a), SAA,
vWF, IL-6, TNF-alpha and ICAM-1 were, in general,
higher in patients compared with controls; however, there
was no clear and consistent difference with regard to the
sCD14 distribution (Table 6), taking into account the large
number of variables tested, and the CD14 C(-260)3T
polymorphism (Table 7), neither in patients nor in controls.
The only exception was CRP, which was slightly elevated in
subjects being in the top quintile of the sCD14 distribution
compared with the combined four lower quintiles, in pa-
tients and in controls, after adjustment for age and gender.
All analyses have been done separately for those with a
history of prior AMI (n  194) without yielding any
different results (data not shown).
DISCUSSION
In this large case-control study including only patients with
stable CAD, we found no independent association between
sCD14 plasma levels or CD14 C(-260)3T gene polymor-
phism with angiographically confirmed CAD. In addition,
there was no consistent association of sCD14 with seropos-
itivity to C. pneumoniae, H. pylori and a combination of
both. Furthermore, sCD14 plasma levels, or CD14 C(-
260)3T gene polymorphism, were not related with a
variety of sensitive systemic markers of inflammation and
hemostasis or lipid parameters. Thus, these data are in
contrast to several reports in the literature and do not
Table 4. Age- and Gender-Adjusted Plasma Levels of sCD14 (g/ml) According to Serostatus
of C. pneumoniae and Serostatus of H. pylori
Mean sCD14 (g/ml)*
Patients
With CAD p Values Controls p Values
Chlamydial LPS (IgG)
Positive 60.9% 4.05 62.4% 4.40
Negative 4.24 0.19 4.24 0.17
Helicobacter pylori (IgG)
Positive 44.2% 4.13 31.3% 4.29
Negative 4.13 0.99 4.34 0.67
Chlamydial LPS and Helicobacter pylori
Both positive 23.4% 4.14 19.0% 4.31
One positive 51.6% 4.05 49.5% 4.41
Both negative 25.0% 4.34 0.26 31.5% 4.22 0.43
*After adjustment for age and gender.
Table 5. Crude and Adjusted OR for Coronary Artery Disease
Associated With sCD14 Plasma Levels and CD14
C(-260)3T Polymorphism
Factor
Partly Adjusted
OR (95% CI)*
Multivariate-Adjusted
OR (95% CI)†
sCD 14 receptor (quintiles)
1st quintile 1reference 1reference
2nd 1.21 (0.76–1.91) 1.13 (0.67–1.91)
3rd 1.11 (0.69–1.77) 1.02 (0.60–1.74)
4th 1.06 (0.66–1.71) 1.06 (0.62–1.81)
5th 1.06 (0.66–1.70) 1.11 (0.65–1.91)
p for trend  0.95 p for trend  0.83
CD14 genotypes
CC 1reference 1reference
CT 1.16 (0.82–1.65) 1.27 (0.86–1.89)
TT 1.17 (0.77–1.78) 1.34 (0.84–2.16)
*Adjusted for age and gender; †Adjusted for age, gender, body mass index, school
education, cigarette smoking, alcohol consumption, history of hypertension, history of
diabetes.
CI  confidence interval; OR  odds ratio; sCD14  soluble CD14.
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suggest an important role for CD14 C(-260)3T gene
polymorphism or sCD14 plasma levels as risk markers for
stable CAD.
Association between CD14 genotype and CAD. Three
recent retrospective studies have reported a positive associ-
ation between CD14 C(-260)3T gene polymorphism and
risk of AMI or CAD (37–39), whereas our study and one
large prospective study (40) found no association. Several
reasons may be responsible for these discrepant findings.
First, in the study by Unkelbach et al. (38), the positive
association reported was confined to post-hoc analysis of
small low-risk subgroups, whereas in the total group of
patients no such association was seen. Second, in the study
by Hubacek et al. (37), the control group was rather small
(n  135), and the frequency of the TT genotype was
considerably lower compared with our study and three
others (38–41). Furthermore, surprisingly, conventional
risk factors were not different between cases and controls in
this study. Third, numbers in the study by Shimada et al.
(39) carried out in a Japanese population were also small (83
controls and 128 patients with angiographically docu-
mented CAD), and a positive association was only seen in
those with a recent AMI (n  81) but not in those with
stable CAD (n  47). The TT genotype was more than
twice as frequent in this ethnically different group compared
with all other reports in Caucasians. In contrast with these
at least partly positive studies, in our large, carefully con-
trolled case-control study, no strong independent associa-
tion between CD14 C(-260)3T gene polymorphism and
risk of CAD could be demonstrated in multivariable anal-
ysis, although a weak relationship cannot be ruled out.
Thus, our data are in accordance with the only so far
published prospective study by Zee et al. (40) who also
found no evidence of a significant association between
CD14 allele and relative risk of future AMI.
Association between sCD14 plasma levels and CAD.
Mean levels of the monocyte-specific activation marker
sCD14 in cases and controls were not different in our study.
As a consequence, the OR for the presence of CAD in the
top quintile of the sCD14 distribution was not significantly
increased in multivariable analysis, compared with the
bottom quintile. Only one study so far has reported on the
potential association between plasma levels of sCD14 and
CAD. In this relatively small study (46), sCD14 levels in
Table 6. Mean Concentrations*† of Various Markers of Inflammation and Hemostasis in
Patients and Controls in the Top Quintile of sCD14 Receptor Distribution Compared With the
Combined Lower Four Quintiles
sCD14
1–4th Quintile
sCD14 5th Quintile
(>5.18 g/ml) p Value
Patients (n  312)
CRP (mg/l)‡ 1.47 2.15 0.03
Fibrinogen (g/l) Clauss method 2.71 2.85 0.14
Nephelometric 2.77 2.94 0.04
Plasma viscosity (mPas) 1.22 1.23 0.74
Leukocyte count (in 103/l) 6.96 6.95 0.96
PAI-1 (activity U/ml)§ 11.6 13.67 0.10
Lp(a) (mg/dl)‡ 16.7 17.4 0.89
SAA (mg/l)‡ 3.41 3.87 0.27
vWF (activity %) 139.2 154.1 0.07
Il-6 (pg/ml)‡ 2.34 2.92 0.06
TNF-alpha (pg/ml)‡ 2.52 2.80 0.80
ICAM-1 (ng/ml) 527.9 559.1 0.19
D-Dimer (ng/ml)‡ 6.01 7.69 0.27
Controls (n  476)
CRP (mg/l)‡ 1.08 1.45 0.03
Fibrinogen (g/l) Clauss method 2.58 2.55 0.57
Nephelometric 2.50 2.51 0.90
Plasma viscosity (mPas) 1.19 1.19 0.49
Leukocyte count (in 103/l) 5.78 5.69 0.62
PAI-1 (activity U/ml)‡ 6.33 7.86 0.04
Lp(a) (mg/dl)‡ 8.69 8.50 0.78
SAA (mg/dl)‡ 2.87 2.91 0.72
vWF (activity %) 134.0 134.9 0.87
II-6 (pg/ml)‡ 1.42 1.46 0.72
TNF-alpha (pg/ml)‡ 1.74 1.79 0.89
ICAM-1 (ng/ml) 499.3 473.7 0.11
D-dimer (ng/ml)‡ 2.50 3.10 0.14
*Adjusted for age and gender by general linear regression; †Arithmetic or if skewed; ‡geometric means.
CRP  C-reactive protein; ICAM  intercellular adhesion molecule; IL  interleukin; Lp(a)  lipoprotein (a); mPa 
millipascal; PAI plasminogen-activator-inhibitor; SAA serum amyloid A; sCD14 soluble CD14; TNF tumor necrosis
factor; wVF  von Willebrand factor.
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patients with stable CAD were not different from controls
but were 41% higher in plasma from patients with unstable
angina, suggesting increased monocyte activation. Thus,
although in both studies no association was found between
sCD14 plasma levels and chronic, stable CAD, there may
still be an important relationship with unstable or acute
disease.
Association between CD14 genotype and sCD14 plasma
levels. We found slightly higher plasma levels of sCD14 in
the TT genotype, compared with CT or CC genotype in
patients (p  0.03), and a tendency to elevated values was
seen in controls (p  0.11). Although no such data are
available from other studies in patients with CAD, similar
results have been reported in patients with ischemic cere-
brovascular disease with plasma levels of the same magni-
tude (43). Such small differences (0.4 to 0.5 g/ml),
however, are unlikely to be clinically relevant.
Association between CD14 genotype, sCD14 plasma
levels and sensitive systemic markers of inflammation.
Assuming that genetic variation of the CD14 receptor with
increased CD14 gene expression might play a role in
atherogenesis, a mechanistic link would consist in its con-
tribution to the inflammatory response seen in this disease
(1). Such effect could result in either increased levels of
sCD14 receptor in plasma but might also be demonstrated
by increased levels of sensitive systemic markers of inflam-
mation, which have been shown to be independently related
to coronary disease in prospective studies. We have mea-
sured a large variety of such markers and were unable to
detect any meaningful relationship with CD14 genotype.
Most of these markers are known to increase after stimula-
tion of various cell types, including macrophages, SMCs or
ECs by LPS. Furthermore, with the exception of CRP, no
other inflammatory marker was associated with plasma
levels of sCD14 (top quintile vs. combined lower four
quintiles). Taking into account the large number of markers
tested, such finding may have occurred by chance alone.
Strengths of this study. We carefully selected cases and
controls and excluded patients with acute coronary syn-
dromes in order to eliminate the possibility of an elevation
of the measured parameters as a result of an acute phase
response. In addition, we carefully recorded the conven-
tional risk factors and investigated their relationship to
sCD14 and CD14 C(-260)3T genotype in order to assess
their potential for confounding and adjusted for them in the
final analysis by means of multivariate methods. In contrast
with other studies, we measured a large variety of sensitive
systemic markers of inflammation to evaluate a potential
contribution of the genetic variation of the LPS receptor or
sCD14 plasma levels to the inflammatory response known
to represent an integral part of the atherosclerotic process.
Study limitations. Several potential limitations of our
study have to be considered. We used a case-control design;
therefore, the temporal relationship of the serum parameters
and disease is difficult to establish. Selection and survival
bias may represent another problem. However, because the
hospital of the University of Ulm Medical Center is the only
hospital serving the city of Ulm and, besides being a tertiary
care center, it also serves as a primary care center. Further-
more, the study comprised all consecutive patients referred
for coronary angiography within a defined time period. To
limit selective survival we restricted the case group to those
with a diagnosis of CAD within less than two years.
Although controls came from the same geographic region as
patients, they were probably healthier than population-
based controls. Furthermore, asymptomatic CAD in these
subjects cannot be ruled out completely because no electro-
cardiogram or coronary angiogram could be obtained in
controls. However, the prevalence of CAD in an asymp-
tomatic middle-age population appears to be low (47), and
selection of controls among subjects who undergo coronary
angiography for various reasons possibly introduces an even
more severe bias. This, however, cannot explain the lack of
a significant association that emerged after control for
confounding factors. Furthermore, although this study did
not have the power to detect a weak association between
sCD14 levels, or the CD14 C(260)3T polymorphism
and CAD, it had a power of 80% to detect an OR of 1.63
(associated with being in the upper quintile of sCD14) and
Table 7. Mean Concentrations*† of Various Markers of
Inflammation and Hemostasis in Patients and Controls
According to CD14 Genotypes
CC or CT TT p Value
Patients (n  312)
CRP (mg/l)‡ 1.64 1.34 0.23
Fibrinogen (g/l) Clauss method 2.73 2.77 0.68
Nephelometric 2.80 2.78 0.82
Plasma viscosity (mPas) 1.22 1.22 0.63
Leukocyte count (in 103/l) 6.99 6.82 0.50
PAI-1 (activity U/ml)‡ 11.73 12.67 0.42
Lp(a) (mg/dl)‡ 15.90 20.76 0.89
SAA (mg/l)‡ 3.57 3.20 0.33
vWF (activity, %) 143.9 134.4 0.22
Il-6 (pg/ml)‡ 2.47 2.31 0.52
TNF-alpha (pg/ml)‡ 2.55 2.39 0.29
ICAM-1 (ng/ml) 536.8 521.5 0.49
D-dimer (ng/ml)‡ 6.35 6.22 0.86
Controls (n  476)
CRP (mg/l)‡ 1.21 1.01 0.15
Fibrinogen (g/l) Clauss method 2.58 2.55 0.97
Nephelometric 2.51 2.45 0.33
Plasma viscosity (mPas) 1.19 1.19 0.59
Leukocyte count (in 103/l) 5.82 5.60 0.19
PAI-1 (activity U/ml)‡ 6.71 6.27 0.51
Lp(a) (mg/dl)‡ 8.77 7.90 0.53
SAA (mg/l)‡ 2.87 3.01 0.72
vWF (activity, %) 133.5 136.7 0.57
Il-6 (pg/ml)‡ 1.41 1.50 0.40
TNF-alpha (pg/ml)‡ 1.75 1.87 0.27
ICAM-1 (ng/ml) 491.6 507.4 0.30
D-dimer (ng/ml)‡ 2.97 2.78 0.72
*Adjusted for age and gender by general linear regression; †Arithmetic or if skewed
‡geometric means.
Abbreviations as in Table 6.
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of 1.59 (associated with the TT genotype), respectively, at
  0.05.
Conclusions. Our results do not confirm an independent
and clinically relevant relationship of CD14 gene polymor-
phism with risk of CAD. The lack of an association
between sCD14 plasma levels and risk of stable CAD or
markers of inflammation and between CD14 genotype and
the inflammatory response constitute novel findings that
contribute to the ongoing discussion on inflammatory path-
ways in atherosclerosis. Therefore, it seems unlikely that, in
the population studied, sCD14 plasma levels or CD14
C(-260)3T genotype are promising tools for risk assess-
ment of stable CAD.
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